Can we modulate the gut microbiome to enhance DMARD efficacy in rheumatoid arthritis?

Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: RBB has no conflicts to declare. RRN has no conflicts to declare. JUS has served as a consultant for Janssen, Novartis, Pfizer, Sanofi, Amgen, UCB, BMS, and AbbVie; and has received funding for investigator-initiated studies from Janssen and Pfizer.